bioRxiv Preprint Server
February 14, 2022
Tudor M. Ionescu, Mario Amend, Tadashi Watabe et al.
1 citation
preprint
Psychedelic compounds have attracted increasing interest in recent years due to their therapeutic potential for psychiatric disorders. Methylenedioxymethamphetamine (MDMA) is currently being investigated in clinical trials to treat post-traumatic stress disorder. To understand the acute effects of psychedelic drugs in vivo, functional MR imaging (fMRI) has been widely used in recent years....
Journal of Humanistic Psychology
February 10, 2022
Terence H. W. Ching, Monnica T. Williams, Sara Reed et al.
10 citations
MDMA (±3,4-methylenedioxymethamphetamine)-assisted therapy (MDMA-AT) was shown in previous clinical trials to have promising efficacy and safety for alleviating treatment-resistant posttraumatic stress disorder (PTSD). However, due to low ethnoracial diversity, the question remains as to whether ethnoracial minority participants would benefit similarly. Thus, a mixed-methods case study was...
Harm Reduction Journal
February 5, 2022
Joseph J Palamar, İbrahim Sönmez
Dance festivals have been shown to be high-risk events for use of drugs such as ecstasy/MDMA and possible adverse effects associated with use. However, few studies have examined what makes festivals such risky environments. We aimed to determine festival-specific risk factors for adverse outcomes related to drug use. In-depth interviews were conducted with 35 key informants in North America who...
European Neuropsychopharmacology
February 3, 2022
Lilian Kloft, Henry Otgaar, Arjan Blokland et al.
17 citations
The entactogen 3,4-Methylenedioxymethamphetamine (MDMA) is increasingly being recognized for its therapeutic potential but is also widespread in nightlife settings where it may co-occur with crime. Since previous research detected impaired verbal memory during acute MDMA intoxication, understanding the drug's ramifications in an applied legal context becomes crucial. We conducted a...
Drug and Alcohol Dependence
February 1, 2022
Christopher R. Nicholas, Julie B. Wang, Allison R. Coker et al.
67 citations
Background Post-traumatic stress disorder (PTSD) is commonly associated with alcohol and substance use disorders (ASUD). A randomized, placebo-controlled, phase 3 trial demonstrated the safety and efficacy of MDMA-assisted therapy (MDMA-AT) for the treatment of severe PTSD. This analysis explores patterns of alcohol and substance use in patients receiving MDMA-AT compared to placebo plus...
Frontiers in Psychiatry
January 24, 2022
Tigran Makunts, Lisa Jerome, Ruben Abagyan et al.
19 citations
3,4-Methylenedioxymethamphetamine (MDMA), is investigated as a treatment for post-traumatic stress disorder and other anxiety-related conditions in multiple placebo-controlled and open label studies. MDMA-assisted therapy is projected for approval by the United States Food and Drug Administration (FDA) and other regulatory agencies worldwide within the next few years. MDMA is a monoamine...
Frontiers in Psychiatry
January 21, 2022
Melina Wiedmann, Sören Kuitunen-Paul, Lukas A Basedow et al.
5 citations
ObjectivesBoth substance use, on the one hand, and the first signs of psychosis, on the other, commonly begin in adolescence. Adolescents with substance use disorder (SUD) frequently show recreational use of cannabis and 3,4-methylenedioxymethamphetamine (MDMA). When attenuated psychotic symptoms (APS) occur during the course of SUD, they are commonly attributed to the cannabis use, neglecting...
bioRxiv (Cold Spring Harbor Laboratory)
January 21, 2022
Konstantin A. Demin, Olga V. Kupriyanova, Вадим А. Шевырин et al.
preprint
Abstract Serotonergic hallucinogenic drugs potently affect human brain and behavior, and have recently emerged as potentially promising agents in psychopharmacotherapy. Complementing rodent studies, zebrafish ( Danio rerio ) is a powerful animal model for screening neuroactive drugs, including serotonergic agents. Here, we test ten different N-Benzyl-2-phenylethylamine (NBPEA) derivatives with...
Psychopharmacology
January 15, 2022
Adrian Hase, M Erdmann, Verena Limbach et al.
33 citations
Abstract Rationale and objectives Differences among psychedelic substances regarding their subjective experiences are clinically and scientifically interesting. Quantitative linguistic analysis is a powerful tool to examine such differences. This study compared five psychedelic substance report groups and a non-psychedelic report group on quantitative linguistic markers of psychological states...
Medieval Mystical Theology
January 2, 2022
R. van Nieuwenhove
ABSTRACT This article considers a key topic from medieval theological anthropology by examining how ecstasy and self-transcendence relate to divine nothingness. It discusses this topic by examining a spiritual classic written by a female author and published in 1538 but largely forgotten, namely, The Evangelical Pearl, which encapsulates central themes from Jan van Ruusbroec and Meister Eckhart...
Drug Science, Policy and Law
2022
Pascoe Mj, S Radley, Simmons Htd
Adulteration poses additional unknown risks to the health of people who use illicit drugs. In this study, we sought to determine the extent and nature of adulteration of ‘MDMA’ in circulation at English summer music festivals in 2021, following Brexit, COVID-19 lockdowns and various regulatory changes overseas. At three festivals in 2019 and 2021, 1648 surrendered substances were analysed with...
Human Psychopharmacology: Clinical and Experimental
2022
Foke L. Van de Blaak, Glenn Dumont
AbstractRationaleMDMA or Ecstasy has made a resurgence in popularity and the majority of users consist of teenagers and adolescents. Therefore, it is important to determine whether MDMA causes long‐term damage and what this damage entails. There is an ongoing debate about possible neurocognitive changes in 3,4‐methylenedioxymethamphetamine (MDMA) users related to MDMA's neurotoxic potential....
2022
Amanda Medeiros Furquim, Tânia Marcourakis
INTRODUÇÃO: O Transtorno de Estresse Pós-Traumático (TEPT) é um transtorno neuropsiquiátrico que se desencadeia após a experiência ou testemunho de um evento psicologicamente traumático. Este distúrbio representa um grande problema de saúde pública mundial, afetando mais de 8 milhões de americanos e custando cerca de US{dollar} 43,2 bilhões por ano aos EUA. Os tratamentos existentes consistem...
Handbook of Substance Misuse and Addictions
2022
Esther Papaseit, Magí Farré, Clara Pérez‐mañá
Public health focused on drug use is considered a balancing act between preventing illicit use of drugs of abuse and ensuring access to drugs/medicines with abuse potential for a medical condition. Whereas clinically relevant drug interactions for medicines are widely recognized and are included in most pharmacovigilance systems, drug interactions with drugs of abuse are mainly underexplored,...
Handbook of Substance Misuse and Addictions
2022
Francis Kin Chiu Chu
MDMA (3,4-methylenedioxymethamphetamine), popularly known as “ecstasy,” “E,” “Adam,” “XTC,” “M&M,” or “Molly,” is a synthetic compound of phenethylamine with stimulant and hallucinogenic properties. It is a common recreational street drug affecting young people particularly at urban dance parties in Hong Kong. MDMA abuse is widely reported in electronic dance music (EDM) festivals all over the...
HPHR Journal
2022
Candice Carpenter
According to the National Survey on Drug Use and Health, in just 2014 alone, over 17 million persons ages 12 or older reported at least a singular lifetime use of the hallucinogenic stimulant, and well-known recreational drug, MDMA, or 3,4- methylenedioxymethamphetamine. Compared to 10 years prior, this was an increase from 11 million people within the same age bracket.21Per the European Centre...
2022
Davi Mello Castanheira, Andréa da Silva Torrão
INTRODUÇÃO: O Transtorno de Estresse Pós-Traumático (TEPT) é definido como uma condição na qual um indivíduo que sofreu um evento traumático revisita a experiência na forma de lembranças, sonhos ou episódios dissociativos de flashback. A psicoterapia é considerada como primeira opção para o tratamento de TEPT, mas também se utiliza a farmacoterapia com os ISRS paroxetina e sertralina. Os...
Journal of Psychopharmacology
2022
Grant Jones, Matthew K. Nock
40 citations
Background: Depression is a major mental health issue worldwide, with high rates of chronicity and non-recovery associated with the condition. Existing treatments such as antidepressant medication and psychological treatments have modest effectiveness, suggesting the need for alternative interventions. Aim: The aim of this study was to examine the relationships between MDMA...
Journal of Psychopharmacology
2022
Grant Jones, Matthew K. Nock
60 citations
Background: Suicide is one of the leading causes of death worldwide and rates within the United States have risen over the past two decades. Hence, there is a critical need for novel tools to treat suicidal ideation and related mental health conditions. 3,4-Methylenedioxymethamphetamine (MDMA)/ecstasy and classic psychedelics may be two such tools. Aims: The aim of this study was to assess...
Frontiers in Psychiatry
2022
S Parker Singleton, Julie B. Wang, Michael C Mithoefer et al.
36 citations
3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) has demonstrated promise in multiple clinical trials. MDMA is hypothesized to facilitate the therapeutic process, in part, by decreasing fear response during fear memory processing while increasing extinction learning. The acute administration of MDMA in healthy controls modifies recruitment...